Company: NMP
Filing Date: 2025-05-06
Form Type: S-1
Source: 0001213900-25-039851
Chunk: 203

Company: NMP Acquisition Corp.
Filing Date: 2025-05-06
Form: S-1
Chunk 203
---
 at VMG Strategic Consulting Inc., a consulting firm specializing in technology infrastructure and strategic business counsel, since August 2024. Prior to VMG Strategic Consulting, Inc., from June 2023 until August 2024, Mr.Benson served as the Founder at Tagd Consulting, where he provided consulting services related to mergers and acquisitions, capital raising and other general advisory services. Mr.Benson also served as Chief Technology Officer at CXApp Inc. from April 2023 until June 2023, and, before joining CXApp Inc., he served as Chief Technology Officer at Inpixon from September 2018 until April 2023. Mr.Benson holds a Master of Business Administration in Business and Data Analytics from the Louisiana State University Shreveport, and a Bachelor of Business Administration in Business from the Memorial University of Newfoundland. Mr.Benson is well qualified to serve on our board of directors because of his significant experience in accounting and finance, as well as information security, cybersecurity and artificial intelligence. Dr. Vanila M. Singhwill become our independent director upon the commencement of trading of our units on Nasdaq. She has served as a Clinical Associate Professor at the Stanford University School of Medicine for over 20 years, focusing on pain management, regional anesthesia and advance ultrasound -guidedprocedures. She also served as the Chief Medical Officer for the U.S. Department of Health and Human Services from June 2017 to July 2019, and as Acting Regional Health Administrator for Region9, which is comprised of certain U.S. states and territories, where she chaired an inter -agencytask force federally required by Comprehensive Addiction and Recovery Act of 2016, authored a report to the U.S. Congress and managed national public and subcommittee meetings and others. Further, Dr. Singh has served in board of directors of certain public companies — including BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company that focused on pain management and addiction medicine, from November 2019 until its acquisition in March 2022, and Virpax Pharmaceuticals Inc. (NASDAQ: VPRX), a specialty pharmaceutical company focused on pioneering advanced healthcare solutions, from July 2020 until August 2024 — and of Lucid Lane Inc., a private company that offers comprehensive telehealth solution for pain, mental health and substance abuse, from April 2020 to April 2023. Dr. Singh holds a B.S. from The University of California at Berkeley, an M.D. from the George Washington University School